The DAISY Project

Denna sida på svenska

Descriptive register study to Asses the treatment reality of type 2 diabetes patients In Sweden

Thomas Nyström and David Nathanson diabetes researchers at the Department of Clinical Science and Education, Södersjukhuset are participating in the DAISY project, a collaboration between a number of clinically active diabetes researchers and Astra Zeneca.

The project carries out epidemiological research that aims to highlight the extent of type 2 diabetes and its harmful consequences, with main focus on cardiovascular disease and social costs.

The group also conducts, with modern epidemiological methods, studies that evaluate various antihyperglycemic agents effects on cardiovascular disease and risk of hypoglycaemia. In the studies published so far, data from the Prescribed Drug Register, the Patient Register and the Cause of Death Register are being used.

The project members have presented their work at several international conferences, including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).


Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
Frederik Persson, Johan Bodegård, Jorma T. Lahtela, Thomas Nyström, Marit E. Jørgensen, Majken Linneman Jensen, David Nathanson et al
Endocrinology, Diabetes & Metabolism, August 2018

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
David Nathanson, Ugne Sabale, Jan W. Eriksson, Thomas Nyström, Anna Norhammar, Urban Olsson, Johan Bodegård
PharmacoEconomics Open (Nov 2017)

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Kåre I Birkeland, Frederik Persson, Marcus Thuresson, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar et al
The Lancet Diabetes & Endocrinology, 2017 Aug 03, Editor's choise

Dapagliflozin Compared to DPP-4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All-cause Mortality in Type 2 Diabetes Patients (CVD-REAL Nordic): a multinational observational study
Frederik Persson, Thomas Nyström, M E Jörgensen, Marcus Thuresson, David Nathanson, Jan W. Eriksson
Diabetes, Obesity and Metabolism, August 2017

Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
Thomas Nyström, Johan Bodegård, David Nathanson, Marcus Thuresson, Anna Norhammar, Jan W. Eriksson
Diabetes, Obesity and Metabolism, June 2017

Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia
Thomas Nyström, Johan Bodegård, David Nathanson, Marcus Thuresson, Anna Norhammar, Jan W. Eriksson
Diabetes Research and Clinical Practice, Volume 123, January 2017, Pages 199-208

Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013
Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, Jan W. Eriksson, David Nathanson
Diabetologia, May 2016

Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Jan W. Erikssona, Johan Bodegard, David Nathanson, Marcus Thuresson, Thomas Nyström, Anna Norhammar
Diabets Research and Clinical Practice , Volume 117, July 2016, Pages 39–47

Cardiovascular DiseasesDiabetes